Name:	abbv_PotentialPaymentsUnderAgreementCertainMilestones
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Research and Development Milestone Expenses

No definition available.

Name:	abbv_ResearchAndDevelopmentMilestoneExpenses
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.

No definition available.

Name:	us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Amount of gain (loss) on sale or disposal of other assets.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Name:	us-gaap_GainLossOnSaleOfOtherAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.

No definition available.

Name:	us-gaap_OtherOperatingIncomeExpenseNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Amount of cash outflow to acquire investments classified as other.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

Name:	us-gaap_PaymentsToAcquireOtherInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Amount of cash inflow from the sale of other assets as part of operating activities.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

Name:	us-gaap_ProceedsFromSaleOfOtherAssets1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Name:	us-gaap_BusinessAcquisitionAxis=abbv_CerevelTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_BusinessAcquisitionAxis=abbv_ImmunoGenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_CounterpartyNameAxis=abbv_SyndesiTherapeuticsSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_CounterpartyNameAxis=abbv_JuvisePharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_CounterpartyNameAxis=abbv_OtherCollaborationArrangementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_CounterpartyNameAxis=abbv_CelsiusTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_CounterpartyNameAxis=abbv_AiadaTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_CounterpartyNameAxis=abbv_NimbleTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: